drugset
drugset / Trial / NCT05727878

Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED

NCT05727878 ↗

Phase 2 Terminated 103 enrolled Combangio, Inc Kala Pharmaceuticals, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of the study is to investigate the safety and efficacy of KPI-012 compared to vehicle in participants who have a documented clinical diagnosis of PCED.

Timeline

Start
2023-02-07
Primary completion
2025-09-29
Completion
2025-10-19

Outcome

Outcome not reported

Stopped: “Lack of efficacy”

Drugs

EvaluationDrugModalityDoseRoute
Subject KPI-012 Unknown 1 unknown Other
Subject KPI-012 Unknown 3 unknown Other

Indications

corneal disorder